Abstract:Objective: To summarize and analyze the postoperative short-term complications of laparoscope-assisted transanal total mesorectal excision (taTME) for rectal cancer patients after neoadjuvant therapy. Methods: A prospectively established database on taTME patients at Peking University Cancer Hospital was screened with the following conditions: data retrieval from June 2016 to August 2018, pathologically confirmed adenocarcinoma, receiving preoperative neoadjuvant chemoradiotherapy or chemotherapy. The transabdominal procedure and the transanal procedure were performed simultaneously in the taTME operation. Occurrence of complications during perioperative period (within postoperative 3 months) in these patients, especially anastomosis-related complications and their management were analyzed. The relevant complications were recorded according to the Clavien-Dindo (CD) grading criteria. The severity of anastomotic leakage and anastomotic stenosis was evaluated according to criteria developed by the International Rectal Cancer Research Group. Results: A total of 29 patients were enrolled in this study. In the 29 patients, 25 (86.2%) were male and 4 (13.8%) were female, the median age was 60 (range, 30 to 72) years, the median body mass index was 25.8 (range, 19.8 to 36.4) kg/m2, the median distance from the tumor to anal verge was 4 (range, 2 to 8) cm. All the patients completed laparoscope-assisted taTME operations successfully without conversion to laparotomy, intra-operative severe complication or death. The median operation time was 300 (range, 198 to 405) minutes, and the median intra-operative blood loss was 100 (range, 50 to 200) ml. All the TME specimens were complete according to the Nagtegaal standard. All the patients underwent prophylactic ileostomy. Hartmann procedure was performed in one case due to poor blood supply in the proximal bowel without the possibility of anastomosis. Anal sphincter preservation rate was 96.6% (28/29). The median postoperative exhaust time was 2 (range, 1 to 10) days, and the median postoperative hospital stay was 9 (range, 7 to 24) days. Fifteen patients (51.7%) had postoperative complications, among which serious complication (CD grade IIIb and above) accounted for 6.9% (2/29). No perioperative death was observed. Five patients (17.2%) presented anastomosis-related complications, including 2 cases of grade C anastomotic leakage due to anastomotic rupture, who underwent abdominal perineal resection 1 month after operation; 2 cases of grade B anastomotic leakage, who improved after conservative treatment; 1 case of grade A anastomotic stenosis, who improved with anal expansion 1 month after operation. The incidence of postoperative infection was 24.1% (7/29), including 6 cases of pelvic infection and 1 case of trocar site infection, all of which were CD grade II. One case had incomplete intestinal obstruction (CD grade II); 1 case had gastroplegia; 1 case had abdominal trocar hernia. All the patients were followed up for a median of 12.0 (range, 3.9 to 29.9) months. Seven cases did not undergo ileal stoma closure. The anal sphincter preservation rate was 75.9% (22/29). Conclusion: Pelvic infection and anastomosis-related complications are common after laparoscope-assisted taTME surgery for rectal cancer patients following neoadjuvant chemoradiotherapy, which require active management and appropriate treatment.

Risk factors and treatment of rectal stenosis after transanal endoscopic microsurgery

Therapy for Benign Rectal Anastomotic Stricture after Surgery for Colorectal Cancer: A Systematic Review

Transanal endoscopic microsurgery for rectal adenomas: single center experience

The application of laparoscopic total mesorectal excision with preservation of anal sphincter for rectal cancer

Long-term outcomes of transanal endoscopic microsurgery for the treatment of rectal neuroendocrine tumors

Prognosis of Patients Over 60 Years Old With Early Rectal Cancer Undergoing Transanal Endoscopic Microsurgery - A Single-Center Experience

Can transanal endoscopic microsurgery effectively treat T1 or T2 rectal cancer?A systematic review and meta-analysis.

Transanal endoscopic microsurgery is a safe and reliable technique even for complex rectal lesions

Transanal Endoscopic Microsurgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer

[Standardized development of transanal endoscopic microsurgery]

A New Treatment Strategy for Mid-Low Rectal Cancer Patients Exhibiting a Clinical Complete or Near-Complete Response to Neoadjuvant Chemoradiotherapy: Transanal Endoscopic Microsurgery ——A Multicenter Prospective Case-control Clinical Trial by MONT-R

Transanal endoscopic microsurgery after endoscopic resection of malignant rectal polyps: a useful technique for indication to radical treatment

[Postoperative short-term complications of laparoscope-assisted transanal total mesorectal excision for rectal cancer after neoadjuvant therapy and their management: a single center report]

Incidence and Risk Factors of Surgical Complications and Anastomotic Leakage after Transanal Total Mesorectal Excision for Middle and Low Rectal Cancer.

Comparison of the efficacy of endoscopic submucosal dissection and transanal endoscopic microsurgery in the treatment of rectal neuroendocrine tumors ≤ 2 cm

Risk Factors of Esophageal Stenosis after Endoscopic Mucosal Resection

[Risk Factor Analysis on Postoperative Complications after Laparoscopic Total Mesorectal Excision with Preventive Terminal Ileostomy and Timing of Stoma Closure in Rectal Cancer].

Transanal Endoscopic Microsurgery Vs. Radical Surgery for Mid-Low Rectal Cancer in Patients with Clinical Complete or Near-Complete Response after Neoadjuvant Chemoradiotherapy.

Efficacy and safety of submucosal tunneling endoscopic resection for upper gastrointestinal submucosal tumors with more than 1-year' follow-up: a systematic review and meta-analysis.

Management of the complications of submucosal tunneling endoscopic resection for upper gastrointestinal submucosal tumors

Surgical complications after different therapeutic approaches for locally advanced rectal cancer.